For comparison with previous reports, we divided cases into CD8+-high and CD8+-low categories at the sample median, noting that this resulted in comparable proportions to studies that have used a cut point defined by its relationship with clinical outcome.8,13 Multivariable analysis of TTR and OS confirmed better outcome for CD8+-high tumours (HR = 0.71, 95% CI = 0.59–0.87, P = 7.2 × 10−4, and HR = 0.71; 95% CI = 0.57–0.88, P = 1.6 × 10−3) (Fig. 2c, d). The gene discussed is CD8A; the disease is neoplasm.